A guardian molecule ensures that liver cells do not lose their identity. The discovery is of great interest for cancer medicine because a change of identity of cells has come into focus as a ...
Interesting Engineering on MSN1d
China advances in radiation defense for cancer therapy and nuclear falloutsShielding against radiation will not only help people survive nuclear fallout but also improve health outcomes for cancer ...
High doses of radiation– such as those from nuclear explosions, power plant accidents, or cancer radiotherapy– break down DNA ...
A breakthrough new therapy has enabled mice to survive exposure to acute radiation, according to a new study that may lead to ...
Researchers developed a coordination n (ZnDHT NM) that targets tumor cells and cancer stem-like cells, enhancing cancer ...
Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.
GlobalData on MSN1d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...
The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...
A combination of new laboratory technology and artificial intelligence is set to make the rapid and precise differentiation of subgroups of brain tumours widely available. An international research ...
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback